<DOC>
	<DOCNO>NCT01269320</DOCNO>
	<brief_summary>This Single -arm , open-label , before-and exploratory trial 90 day Femarelle ® improve NAFLD metabolic syndrome . Ingestion Femarelle improve non alcoholic steatohepatitis metabolic syndrome patient suffer condition . Subjects receive treatment Femarele 530 mg ( 1 capsule twice day ) 90 day monitor study treatment additional 4 week .</brief_summary>
	<brief_title>Natural Soybean-derived Femarelle ®for Patients With Non Alcoholic Fatty Liver Disease</brief_title>
	<detailed_description />
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>1 . Biopsy proven NASH 2 . If suffer diabetes may treat 2 oral medication , stable dos 2 month . 3 . If participate sexual activity could lead pregnancy , study volunteer must agree two reliable method contraception use simultaneously receive protocolspecified medication 1 month stop medication . NOTE : Hormonalbased method alone sufficient . At least two follow method MUST use appropriately unless documentation menopause , sterilization , azoospermia present : Condoms ( male female ) without spermicidal agent . Condoms recommend appropriate use contraception method effective prevent HIV transmission Diaphragm cervical cap spermicide IUD Hormonalbased contraception Study subject reproductive potential ( girl reach menarche woman postmenopausal least 24 consecutive month undergone hysterectomy and/or bilateral oophorectomy eligible without require use contraceptive . Written oral documentation communicate clinician clinician 's staff require one following : Physician report/letter Operative report source documentation patient record ( laboratory report azoospermia require document successful vasectomy ) Discharge summary Laboratory report azoospermia FSH measurement elevate menopausal range establish report laboratory . 4 . Ability willingness subject legal guardian/representative provide inform consent . 1 . Pregnancy BreastFeeding 2 . Continuous use follow medication 3 day within 30 day study entry : Immunosuppressives Immune modulators Systemic glucocorticoid Antineoplastic agent 3 . Active drug alcohol use dependence , opinion site investigator , would interfere adherence study requirement . 4 . Serious illness require systemic treatment and/or hospitalization within 30 day prior entry . 5 . Surgery within previous 3 month . 6 . Any serious infectious , cardiac , pulmonary , kidney disease 7 . Hypersensitivity Femarelle ® 8 . Malignancy uterus breast 9 . Past thromboembolic event</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2011</verification_date>
</DOC>